Zdrowie i gospodarka · 28/03/2012

FDA Releases Draft Guidance on Bioequivalence Recommendations for Iron Sucrose Injection

The Food and Drug Administration (FDA) has released a draft guidance document titled 'Bioequivalence Recommendations for Iron Sucrose Injection' to provide industry-specific recommendations for designing bioequivalence studies to support abbreviated new drug applications (ANDAs) for iron sucrose injection, a treatment for iron deficiency. The FDA aims to facilitate the development of iron sucrose injection by offering detailed guidance on bioequivalence studies.